Google Search as an Additional Source in Systematic Reviews

Piasecki, Jan; Waligóra, Marcin; Dranseika, Vilius

doi:10.1007/s11948-017-0010-4

Cited by 74 publications

(60 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many innovations in technology are initially published in these forms. There are some limitations to GS (eg, the search algorithm can personalize the search to the user, thus hindering replicability) 30 . Additionally, studies on GS have suggested the search should be limited to the first few pages due to diminishing returns 31 .…”

Section: Methodsmentioning

confidence: 99%

Using clinical reasoning ontologies to make smarter clinical decision support systems: a systematic review and data synthesis

Dissanayake

Colicchio

Cimino

2019

Journal of the American Medical Informatics Association

View full text Add to dashboard Cite

Objective The study sought to describe the literature describing clinical reasoning ontology (CRO)–based clinical decision support systems (CDSSs) and identify and classify the medical knowledge and reasoning concepts and their properties within these ontologies to guide future research. Methods MEDLINE, Scopus, and Google Scholar were searched through January 30, 2019, for studies describing CRO-based CDSSs. Articles that explored the development or application of CROs or terminology were selected. Eligible articles were assessed for quality features of both CDSSs and CROs to determine the current practices. We then compiled concepts and properties used within the articles. Results We included 38 CRO-based CDSSs for the analysis. Diversity of the purpose and scope of their ontologies was seen, with a variety of knowledge sources were used for ontology development. We found 126 unique medical knowledge concepts, 38 unique reasoning concepts, and 240 unique properties (137 relationships and 103 attributes). Although there is a great diversity among the terms used across CROs, there is a significant overlap based on their descriptions. Only 5 studies described high quality assessment. Conclusion We identified current practices used in CRO development and provided lists of medical knowledge concepts, reasoning concepts, and properties (relationships and attributes) used by CRO-based CDSSs. CRO developers reason that the inclusion of concepts used by clinicians’ during medical decision making has the potential to improve CDSS performance. However, at present, few CROs have been used for CDSSs, and high-quality studies describing CROs are sparse. Further research is required in developing high-quality CDSSs based on CROs.

show abstract

Section: Methodsmentioning

confidence: 99%

Using clinical reasoning ontologies to make smarter clinical decision support systems: a systematic review and data synthesis

Dissanayake

Colicchio

Cimino

2019

Journal of the American Medical Informatics Association

View full text Add to dashboard Cite

show abstract

“…Additionally, in a validation search in Google Scholar, 32,33 two references were inserted through manual search. 25,34 Seven clinical trial records specifically related to ACE inhibitors or ARBs were found on ClinicalTrials.gov.…”

Section: Search Resultsmentioning

confidence: 99%

Angiotensin-Converting Enzyme inhibitors (ACE inhibitors) and Angiotensin II Receptor Blockers (ARBs) role in SARS-CoV-2 infection: A Rapid Systematic Review

Oliveira

Matuoka

Parreira

et al. 2020

Preprint

View full text Add to dashboard Cite

No medications specific treatments are known to be effective for COVID-19 until now. Several drug therapies are being used to optimize supportive care to relieve symptoms. Some observational and essentially theoretical studies have shared opposite opinions regarding the use of ACE inhibitors and ARBs in SARS-CoV-2 infected patients. Therefore, the aim of this review is to evaluate the relationship between ACE inhibitors and ARBs use and clinical effects in COVID-19 patients to guide clinicians for their medical early decision. Electronic searches were conducted on Embase, Medline via PubMed and ClinicalTrials.gov. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement was followed and adapted the research as a rapid review. Due to the emergency of the COVID-19 pandemic, any research in English, Portuguese or Spanish that discuss the mechanism of action, in vitro studies and those that draw conclusions based on observational or experimental studies were included. No studies were excluded based on the participant’s clinical or demographical characteristics. The risk of bias was assessed by one reviewer and checked by a second reviewer, using the Joanna Briggs Institute Checklist for Case Series. Any other mechanistic, theoretical or in vitro studies were evaluated as high risk of bias for clinical. Out of 64 studies retrieved, 17 were included in the review. Three studies suggest that both medications may increase the risk of worsening COVID-19, while three suggest they could be beneficial. Currently, there are seven ongoing trials on ARBs and ACE inhibitors. The available evidence does not allow us to draw definite conclusions on either harm or benefit of these medications in the presence of COVID-19. Discontinuing the therapy may be hasty and more robust evidence-based research is needed.

show abstract

“…It is usually considered that a MEDLINE search alone is not adequate for answering relevant questions [12]. In accordance, we have increased the scope of our search with GOOGLE searcher, since it is commonly used in all types of searches and has specific tools for systematic reviews and scientific searches [70,71].…”

Section: Discussionmentioning

confidence: 99%

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)

Sampayo-Cordero

Miguel-Huguet

Malfettone

et al. 2020

IJERPH

View full text Add to dashboard Cite

Background: Case reports are usually excluded from systematic reviews. Patients with rare diseases are more dependent on novel individualized strategies than patients with common diseases. We reviewed and summarized the novelties reported by case reports in mucopolysaccharidosis type II (MPS-II) patients treated with enzyme replacement therapy (ERT). Methods: We selected the case reports included in a previous meta-analysis of patients with MPS-II treated with ERT. Later clinical studies evaluating the same topic of those case reports were reported. Our primary aim was to summarize novelties reported in previous case reports. Secondary objectives analyzed the number of novelties evaluated in subsequent clinical studies and the time elapsed between the publication of the case report to the publication of the clinical study. Results: We identified 11 innovative proposals in case reports that had not been previously considered in clinical studies. Only two (18.2%) were analyzed in subsequent nonrandomized cohort studies. The other nine novelties (81.8%) were analyzed in later case reports (five) or were not included in ulterior studies (four) after more than five years from their first publication. Conclusions: Case reports should be included in systematic reviews of rare disease to obtain a comprehensive summary of the state of research and offer valuable information for healthcare practitioners.

show abstract

Google Search as an Additional Source in Systematic Reviews

Cited by 74 publications

References 3 publications

Using clinical reasoning ontologies to make smarter clinical decision support systems: a systematic review and data synthesis

Using clinical reasoning ontologies to make smarter clinical decision support systems: a systematic review and data synthesis

Angiotensin-Converting Enzyme inhibitors (ACE inhibitors) and Angiotensin II Receptor Blockers (ARBs) role in SARS-CoV-2 infection: A Rapid Systematic Review

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)

Contact Info

Product

Resources

About